APLM Apollomics, Inc. Total Debt to Capital

Apollomics, Inc. (APLM) develops therapies for rare oncological pathologies, securing exclusive sales through its patent portfolio. The business stability is bolstered by a staff of leading oncologists and clinical trial experts. With the launch of webreltinib, Apollomics, Inc. (APLM) will gain full pricing power via its unique inhibitors. This price chart reflects that the total debt-to-equity ratio is 0.00.

The specific nature of Apollomics, Inc. (APLM) as a biotech firm with fixed R&D costs and a licensing model minimizes the need for capital expenditures, making the management of debt capital critically important. This metric compares total credit obligations to net owner assets, allowing the total liabilities-to-equity ratio to assess the degree of financial leverage and the risks of potential default should the market value of shares fluctuate.